{"paper_id":"819337f7-3041-41cc-a14e-18d4406101f3","body_text":"Subscribe to RSS\nDOI: 10.1055/s-2003-42279\n© Georg Thieme Verlag Stuttgart · New York\nCOX-2-Expression in extragenitalen Endometrioseläsionen als neuer Therapieansatz?\nCOX-2-Expression in Extragenital Endometriosis Lesions as a Novel Therapeutical Approach?Publication History\nPublication Date:\n23 September 2003 (online)\nZusammenfassung\nFragestellung: Die extragenitale Endometriose ist eine seltene Sonderform der Endometriose, bei\nder durch das invasive, metastatische Wachstum das tumorähnliche Verhalten der Erkrankung\nbesonders deutlich wird. Cyclooxygenase (COX)-2 ist ein Schrittmacherenzym der Prostaglandinsynthese,\ndas insbesondere bei inflammatorischen und malignen Prozessen exprimiert wird. In\ndieser Studie sollte untersucht werden, ob in extragenitaler Endometriose COX-2 exprimiert\nwird.\nMaterial und Methoden: Von 13 Frauen mit extragenitaler Endometriose wurden Gewebeproben von rektaler und\nvaginaler Endometriose, Narbenendometriose und Endometriose des Omentum majus gewonnen.\nDie COX-2-Expression wurde immunohistochemisch untersucht.\nErgebnisse: Es zeigte sich eine Ü berexpression in glandulärem Drüsenepithel in allen Gewebeproben\nund eine schwache bis mittlere Expression in der Hälfte der untersuchten Proben.\nZum Zeitpunkt der Operation durchgeführte Hormontherapien hatten keinen Einfluss\nauf die COX-2-Expression.\nSchlussfolgerung: Die hohe COX-2-Expression in der extragenitalen Endometriose korreliert möglicherweise\nmit der Pathogenese der Endometriose.\nAbstract\nObjective: Extragenital endometriosis is a rare form of endometriosis. Due to its invasive\nand metastatic properties it resembles some features of malignant tumours. Cyclooxygenase\n(COX)-2 is a rate-limiting enzyme in the biosynthesis of prostaglandins and is mainly\nexpressed in inflammatory and malignant processes. In this study we investigated\nthe COX-2 expression in extragenital endometriosis.\nMaterial and Methods: Tissue was obtained of 13 women with rectal and vaginal endometriosis, scar endometriosis\nand endometriosis of the omentum majus. The COX-2 expression was investigated by\nimmunohistochemistry.\nResults: In the glandular epithelium a COX-2 overexpression was found in all cases and in\nthe stroma a weak to moderate COX-2 expression was found in half of the cases. A\nhormonal therapy at the time of surgery had no influence on the COX-2 expression\nin extragenital endometriosis.\nConclusion: The high COX-2 expression in extragenital endometriosis is believed to be strongly\ncorrelated with the pathological abnormalities this of disease.\nSchlüsselwörter\nEndometriose - extragenital - Cyclooxygenase - COX-2 - Prostaglandine - Therapie\nKey words\nEndometriosis - extragenital - cyclooxygenase - COX-2 - prostaglandins - therapy\nLiteratur\n- 1 Attia G R, Zeitoun K, Edwards D, Johns A, Carr B R, Bulun S E. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000; 85 2897-2902\n- 2 Berqvist A. Extragenital Endometriosis. Eur J Surg. 1992; 158 7-12\n- 3 Berqvist A. Different types of extragenital endometriosis: a review. Gynecol Endocrinol. 1993; 7 207-221\n- 4 Bulun S E, Zeitoun K M, Takayama K, Sasano H. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 2000; 6 413-418\n- 5 Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N, Yamamoto T, Honda M. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol. 2002; 48 50-56\n- 6 Cornillei F J, Oosterlynck D, Lauweryns J M, Koninckx P R. Deeply infiltrating pelvic endometriosis: Histology and clinical significance. Fertil Steril. 1990; 53 978-983\n- 7 Davies G, Martin L A, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002; 13 669-678\n- 8 Dawood M Y. Peritoneal fluid prostaglandins and prostaniods in women with endometriosis, chronic pelvic inflammatory disease, and pelvic pain. Am J Obstet Gynecol. 1984; 173 125-134\n- 9 Denkert C, Köbel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002; 160 893-903\n- 10 Dormond O, Foletti A, Paroz C, Ruegge C. NSAIDs inhibit αVβ3 integrin mediated and Cdc42/Rac dependent endothelial-cell spreading, migration and angiogenesis. Nature Med. 2001; 7 1041-1047\n- 11 DuBois R N, Abramson S B, Crafford L, Gupta R A, Simon L S, VanDePutte L B, Lipsky P E. Cyclooxygenase in biology and desease. FSAEB J. 1998; 12 1063-1073\n- 12 Ferrandina G, Legge F, Ranelleti F O, Zannoni G F, Maggiano N, Evangelisti A, Manusco S, Scambia G, Lauriola L. Cyclooxygenase-2 expression in endometrial carcinoma, correlation with clinicopthologic parameters and clinical outcome. Cancer. 2002; 95 801-807\n- 13 Form D M, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med. 1983; 172 214-218\n- 14 Gaetje R, Kotzian S, Herrmann G, Baumann R, Starzinsky-Powitz A. Invasiveness of endometriotic cells in vitro. Lancet. 1995; 150 1463-1464\n- 15 Gebel H M, Braun D P, Tambur A, Frame D, Rana N, Dmowski W P. Spontaneus apoptosis of endometrios is impaired in women with endometriosis. Fertil Steril. 1998; 69 1042-1047\n- 16 Graeber J E, Glase B M, Setty B NY, Jerdan J A, Walega R W, Stuart M J. 15-Hydroxyeicosathtraenoic acid stimulates migration of human retinal microvessels. Prostaglandins. 1990; 39 665-673\n- 17 Half E, Tang X M, Gwyn K, Sahin A, Wathen K, Sinicrope F A. Cyclooxygenase-2 expression in human breast cancer and adjacent ductal carinoma in situ. Cancer Res. 2002; 62 1676-1681\n- 18 Hsu A L, Ching T T, Wang D S, Song X, Rangnekar V M, Chen C S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Act activation in human prostate cancer cells independently of Blc-2. J Biol Chem. 2000; 275 11397-11407\n- 19 Jones R L, Kelly R W, Critchley H OD. Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Hum Reprod. 1997; 12 1300-1306\n- 20 Lessey B A, Metzger D A, Haney A f, McCarthy K S. Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril. 1989; 51 409-415\n- 21 Masferrer J L, Leahy K M, Koki A T, Zweifel B S, Stele S L, Woerner B M, Edwards D A, Flickinger A G, Moore R J, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000; 60 1306-1311\n- 22 Muzii L, Riccardo M, Btunetti L, Orlando G, Michelotto B, Pancini P B. Atypical endometriosis revisited: clinical and biochemical evaluation of the different forms of superficial implants. Fertil Steril. 2000; 74 736-742\n- 23 Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutpic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod. 2001; 16 561-566\n- 24 Ryu H S, Chang K H, Yang H W, Kim M S, Kwan H C, Oh K S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol. 2000; 76 320-325\n- 25 Sheng H, Shao J, Morrow J D, Beauchamp R D, DuBois R N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58 362-366\n- 26 Subbarabaiah K, Telang T, Ramonetti J T, Araki R, DeVito B, Weksler B B, Dannenberg A J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cell. Cancer Res. 1996; 56 4424-4429\n- 27 Ueki M. Histologic study of endometriosis and examination of lymphatic draining in and from the uterus. Am J Obstet Gynecol. 1991; 165 201-209\n- 28 Vernon M W, Beard J, Granve K, Wilson E A. Classification of endometriotic implants by morphologic appearance and capacity to synthesize prostaglandin F. Fertil Steril. 1986; 46 801-806\n- 29 Zhang L, Yu J, Park B H, Kinlzler K W, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 2000; 290 982-989\nPriv.-Doz. Dr. med. Dr. phil. Andreas D. Ebert\nDeutsches Endometriose Kompetenz- und Experten-Netzwerk (DEKEN)/Endometriosezentrum\nBerlin\nFrauenklinik und Poliklinik\nCharité-Universitätsmedizin Berlin\nCampus Benjamin Franklin\nHindenburgdamm 30\n12200 Berlin\nEmail: andreas.ebert@medizin.fu-berlin.de","source_license":"public-domain-us","license_restricted":false}